ID   153.8E2.D10.D6.12.12
AC   CVCL_J992
SY   153.8E2D10D6.12.12; 12.12; CHIR-12.12
DR   ABCD; ABCD_AC977
DR   ATCC; PTA-5543
DR   Wikidata; Q54582075
RX   Patent=US20070098718;
RX   Patent=US20070218060;
RX   Patent=US8333970;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5543.
CC   Registration: Chiron Master Culture Collection; CMCC 12056 (CMCC #12056).
CC   Monoclonal antibody isotype: IgG1, kappa.
CC   Monoclonal antibody target: UniProtKB; P25942; Human CD40.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_2199 ! Sp2/0-Ag14
CA   Hybridoma
DT   Created: 11-02-13; Last updated: 21-03-23; Version: 8
//
RX   Patent=US20070098718;
RA   Long L., Luqman M., Yabannavar A., Zaror I.;
RT   "Methods of therapy for B cell-related cancers.";
RL   Patent number US20070098718, 03-May-2007.
//
RX   Patent=US20070218060;
RA   Long L., Luqman M., Yabannavar A., Zaror I.;
RT   "Use of antagonist anti-CD40 monoclonal antibodies for treatment of
RT   multiple myeloma.";
RL   Patent number US20070218060, 20-Sep-2007.
//
RX   Patent=US8333970;
RA   Aukerman S.L., Jallal B., Luqman M.;
RT   "Methods of monitoring the efficacy of anti-CD40 antibodies in
RT   treating a subject having an inflammatory or autoimmune disease.";
RL   Patent number US8333970, 18-Dec-2012.
//